Amidation Company Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Amidation Company General Information
Description
Developer of healthcare technology intended to design therapeutic and diagnostic tools for diseases associated with the maturation of amidated peptide hormones. The company offers biomarker-guided diagnostic tools, vascular system targeting therapeutic strategies, GMP production planning, and early clinical development work, enabling doctors and researchers to develop treatments for diseases such as Alzheimer's and dementia.
Contact Information
Website
amidation.deCorporate Office
- Neuendorfstraße 15B
- 16761 Hennigsdorf
- Germany
Corporate Office
- Neuendorfstraße 15B
- 16761 Hennigsdorf
- Germany
Amidation Company Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 01-Jul-2026 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A1) | 24-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC | 01-Jan-2021 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Amidation Company Patents
Amidation Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026099243-A1 | Modified and unmodified peptidyl-glycine alpha-amidating monooxygenase (pam) for use in the treatment or prevention of cerebral hypoperfusion for the improvement of cerebral blood flow (cbf) | Pending | 05-Nov-2024 | ||
| WO-2026099249-A1 | Modified and unmodified peptidylglycine alpha-amidating monooxygenase (pam) for use in subjects having increased amyloid-beta and/or phospho-tau-protein load and/or neuroinflammation | Pending | 05-Nov-2024 | ||
| WO-2026046982-A1 | A method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (iect) | Pending | 26-Aug-2024 | ||
| US-20260226155-A1 | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects | Pending | 26-Aug-2024 | ||
| WO-2026046978-A1 | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects | Pending | 26-Aug-2024 | C07K16/26 |
Amidation Company Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brandenburg Kapital | Venture Capital | Minority | ||
| Neuropep GmbH | Venture Capital | Minority |
Amidation Company FAQs
-
When was Amidation Company founded?
Amidation Company was founded in 2020.
-
Where is Amidation Company headquartered?
Amidation Company is headquartered in Hennigsdorf, Germany.
-
What industry is Amidation Company in?
Amidation Company’s primary industry is Drug Discovery.
-
Is Amidation Company a private or public company?
Amidation Company is a Private company.
-
What is Amidation Company’s current revenue?
The current revenue for Amidation Company is .
-
How much funding has Amidation Company raised over time?
Amidation Company has raised $1.7M.
-
Who are Amidation Company’s investors?
Brandenburg Kapital and Neuropep GmbH have invested in Amidation Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process